ArticleCase reports in endocrinology2025
Rare Conditions of Hyperandrogenism Through Lifespan: A Case Series.
Article in Case reports in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A wide spectrum of clinical entities can lead to pre and postmenopausal hyperandrogenism, which is characterized by slow or more rapid onset of virilizing symptoms (menstrual irregularities, hirsutism, androgenetic alopecia). Functional hyperandrogenism in the context of polycystic ovary syndrome (PCOS) remains the most prevalent cause for hyperandrogenism both in pre and postmenopausal females; however, other clinical entities such as ovarian hyperthecosis and benign or malignant neoplasms (e.g., adrenal androgen-secreting adenomas and ovarian tumors of androgen-secreting cells) are often challenging to diagnose. Laboratory testing should include measurement of testosterone, sex hormone binding globulin (SHBG), gonadotropins, estradiol, androstenedione, dehydroepiandrosterone sulfate (DHEA-S), and 17-OH-progesterone values, as well as markers of other endocrine disorders leading to secondary hyperandrogenism, especially Cushing's syndrome. Testosterone values of more than 150 ng/dL generally require further investigation, and increased DHEA-S (more than 700 μg/dL) is suggestive of adrenal androgen-secreting tumors. Androgen suppression during prolonged dexamethasone test can facilitate differential diagnosis between adrenal and ovarian androgen excess production and point to autonomous production in case of tumors. In case of smaller ovarian tumors (e.g., Leydig cell), imaging might not be diagnostic, so that in case of high clinical suspicion, selective ovarian catheterization can be a valuable tool, when available. In this paper, we highlight four rare conditions of hyperandrogenism beyond PCOS, each reflecting specific stages or challenges across the female lifespan. We suggest that detailed biochemical testing and high clinical suspicion should promptly lead to valuable invasive diagnostic tools (ovarian catheterization/laparoscopy) in case imaging is not diagnostic.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.